152Tb-PSMA-617的临床前研究与首次人体PET/CT显像
本研究探索了terbium-152(152Tb)标记的PSMA-617在前列腺癌PET/CT显像中的应用:临床前小鼠实验显示152Tb-PSMA-617可清晰显示PSMA阳性肿瘤,随后首次用于一名转移性去势抵抗性前列腺癌(mCRPC)患者,注射140 MBq后25小时内PET/CT图像具有诊断质量,可检出与68Ga-PSMA-11 PET/CT相同的转移灶及局部复发灶。
要点
- 152Tb-PSMA-617在临床前小鼠模型中可特异性显像PSMA阳性肿瘤。
- 首次人体应用显示注射140 MBq后25小时内PET/CT图像具诊断质量。
- 患者图像可检出与68Ga-PSMA-11 PET/CT一致的转移灶和局部复发。
核心结论
- 152Tb-PSMA-617可成功制备、完成临床前测试并首次用于mCRPC患者PET/CT显像。
- 该工作可能为其他铽放射性核素(尤其是161Tb)的临床应用铺平道路。
研究设计与样本
- 临床前研究加首次人体病例应用:152Tb由CERN/ISOLDE通过散裂反应生产,经色谱法化学分离后用于标记PSMA-617。
- 临床前在小鼠中进行体外表征和PET/CT显像;临床用于一名mCRPC患者,注射140 MBq后25小时内行PET/CT。
主要发现
- 152Tb-PSMA-617在体外表现出与177Lu标记对应物相似的特征。
- 小鼠PET/CT可显示PSMA阳性PC-3 PIP肿瘤,而PSMA阴性PC-3 flu肿瘤无摄取。
- 患者PET/CT图像具有诊断质量,尤其后期时间点图像,可检出与68Ga-PSMA-11 PET/CT(注射后45分钟)相同的转移灶和局部复发肿瘤。
临床怎么用
- 首次人体应用提示152Tb-PSMA-617可用于mCRPC的PET/CT显像,但仅基于一例患者,尚不能常规临床使用。
- 后期时间点图像诊断质量更佳,提示显像时间窗可适当延后。
局限性
- 首次人体应用仅纳入一名mCRPC患者,样本量极小。
- 研究为临床前加个案报道,未评估诊断准确性、重复性或与其他显像剂的系统比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: For almost a decade, terbium radioisotopes have been explored for their potential theragnostic application in nuclear medicine: 152Tb and 155Tb are the radioisotopes identified for PET or SPECT imaging, while 149Tb and 161Tb have suitable decay characteristics for α- and combined β-/Auger-e--therapy, respectively. In the present study, the application of 152Tb, in combination with PSMA-617 for imaging of prostate-specific membrane antigen (PSMA)-positive prostate cancer, was demonstrated in a preclinical setting and in a patient with metastatic castration-resistant prostate cancer (mCRPC). RESULTS: 152Tb was produced at the ISOLDE facility at CERN/Geneva, Switzerland, by spallation, followed by on-line mass separation. The chemical separation was performed at Paul Scherrer Institute using chromatographic methods, as previously reported. 152Tb was employed for labeling PSMA-617, and the radioligand was extensively investigated in vitro to demonstrate similar characteristics to its 177Lu-labeled counterpart. Preclinical PET/CT imaging studies performed with mice enabled visualization of PSMA-positive PC-3 PIP tumors, while uptake in PSMA-negative PC-3 flu tumors were absent. Based on these promising preclinical results, 152Tb was shipped to Zentralklinik Bad Berka, Germany, where it was used for labeling of PSMA-617, enabling PET imaging of a patient with mCRPC. PET/CT scans were performed over a period of 25 h post injection (p.i.) of the radioligand (140 MBq). The images were of diagnostic quality, particularly those acquired at later time points, and enabled the detection of the same metastatic lesions and of local recurrent tumor as previously detected by 68Ga-PSMA-11 PET/CT acquired 45 min p.i. CONCLUSIONS: The results of this study demonstrate the successful preparation and preclinical testing of 152Tb-PSMA-617 and its first application in a patient with mCRPC. This work could pave the way towards clinical application of other Tb radionuclides in the near future, most importantly 161Tb, which has promising decay characteristics for an effective treatment of mCRPC patients.
引用
- Müller C, Singh A, Umbricht CA, et al. Preclinical investigations and first-in-human application of 152Tb-PSMA-617 for PET/CT imaging of prostate cancer. EJNMMI Res. 2019. PMID: 31346796. doi:10.1186/s13550-019-0538-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。